News

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part Two)

November 20, 2023

In part two of an interview with Thomas Langenickel, MD, chief medical officer at Ethris, Langenickel highlights the challenges in developing mRNA therapeutics for pulmonary diseases.

Consent Decrees Entered Against Utah Supplement Manufacturer and Distributors

November 20, 2023

Consent decrees were issued against Evig LLC, of St. George, Utah, and Premium Production LLC, of St. George, Utah, for unapproved dietary supplements.

Consent Decree Entered Against Arizona Company

November 20, 2023

The US District Court for the District of Arizona entered into consent decree against Smart Women’s Choice and its CEO to stop the company from distributing unapproved contraceptive drugs.

Discussing the Origins of the mRNA Therapeutics Field (Part Two)

November 17, 2023

Andy Geall, co-founder and chief development officer at Replicate Bioscience continues the discussion on the development history of mRNA therapeutics.

Autifony Signs $770.5 Million License and Collaboration with Jazz Pharmaceuticals

November 16, 2023

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

Twist Bioscience Launches Gene Synthesis Service

November 16, 2023

Twist Bioscience now offers its Express Genes rapid gene synthesis service at its Wilsonville, Ore. manufacturing facility.

Lonza Launches New Cell Line for Higher Potency Antibody Development

November 16, 2023

Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.

3M Health Care Launches New Chromatographic Clarifier

November 15, 2023

The 3M Harvest RC Chromatographic Clarifier, BT500 is the latest addition to the company’s chromatographic clarifier portfolio.

Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies

November 15, 2023

Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.

FDA Approves First Recombinant Treatment for Rare Blood Clotting Disorder

November 14, 2023

Adzynma provides a replacement for low levels of the ADAMTS13 enzyme in patients with congenital thrombotic thrombocytopenic purpura.